See What HealthDay Can Do For You
Contact Us

Prolonged AIDS Treatment May Help Control Hepatitis B

Highly active antiretroviral therapy is beneficial in patients co-infected with hepatitis B virus

WEDNESDAY, July 22 (HealthDay News) -- In patients who are co-infected with HIV and the hepatitis B virus, prolonged use of highly active antiretroviral therapy (HAART) may help control hepatitis B virus infection and delay or prevent liver complications, according to a study in the May/June issue of HIV Clinical Trials.

Tsan Lee, of the Wake Forest University Health Sciences in Winston-Salem, N.C., and a colleague reviewed 72 chart records of primarily African-American male patients (median age, 39 years) who received highly active antiretroviral therapy between 1990 and 2008.

The researchers found that prolonged use of hepatitis B virus-active HAART was associated with an increased clearance of HBeAg and HBsAg (odds ratios, 2.66 and 1.54, respectively). The rate of diagnosis of liver-related complications and death was 24.6 and 10.5 per 1,000 patient-years, respectively.

"Those with higher alanine aminotransferase levels at presentation seem to have higher risk of being diagnosed with cirrhosis during the first few years of follow-up," the authors conclude. "Other factors such as low nadir CD4 counts and hepatitis C virus co-infection might increase the risk of liver complications as well."

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.